ROBOSENSE
13.3.2021 03:32:07 CET | Business Wire | Press release
RoboSense ( https://robosense.ai/ ) announced the launch of China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery of the automotive-grade solid-state LiDAR RS-LiDAR-M1 for contract projects in Q2 this year.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210312005303/en/
At the CES2021 in January this year, RoboSense has officially unveiled the SOP version of the automotive-grade LiDAR RS-LiDAR-M1, which features a slim design, excellent performance, and reliable point cloud quality. Since July last year, the RS-LiDAR-M1 has successively received a number of orders for mass-production vehicle models around the world, among which, the first customer was an OEM from North America. In December last year, the RS-LiDAR-M1 samples were shipped to this OEM customer in batches, and became the world's first mass-production-ready automotive-grade MEMS solid-state LiDAR delivered.
Two days ago, Inceptio released the self-driving system "Xuanyuan" equipped with RoboSense solid-state LiDAR, and the two parties announced the partnership that the mass-produced L3 heavy-duty freight truck equipped with "Xuanyuan" system will be launched on the market by the end of 2021.
As a world-leading smart LiDAR supplier, RoboSense has reached in-depth cooperation with Inceptio from 2019 to provide high-performance automotive-grade MEMS solid-state LiDAR RS-LiDAR-M1 for Inceptio’s "Xuanyuan" system, the first full-stack self-developed autonomous trucking system for mass production. Inceptio develops the ULRS (ultra-long-range sensing), ARC (adaptive robust control) and FEAD (fuel-efficient autonomous driving) algorithms, and the ULRS can make the system perceive an ultra-long distance of up to 1,000 meters with a margin of error standing below 5%.
In June 2019, Inceptio has worked with Dongfeng Trucks and SINOTRUK respectively to developed L3 autonomous heavy-duty trucks. By the end of 2021, the mass-produced L3 heavy-duty trucks equipped with Inceptio’s "Xuanyuan" system with RoboSense LiDAR inside will be delivered to clients.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. Market-oriented, the company provides customers with various Smart LiDAR perception system solutions, including the MEMS and Mechanical types LiDAR HWs, fusion HW unit, and the AI-based fusion systems. To date, RoboSense LiDAR systems have been widely applied to the future mobility, including autonomous driving passenger cars, RoboTaxi, RoboTruck, RoboBus, automated logistics vehicles and intelligent road by domestic and international autonomous driving technology companies, OEMs, and Tier1 suppliers. https://robosense.ai/
About Inceptio
Inceptio Technology was founded in April 2018, with an aim to build a nation-wide freight network using autonomous driving trucks.
We focus on the transformation of line-haul logistics by providing a more secure, efficient, and economical Transportation-As-A-Service (Taas) to logistic customers. This is to be achieved with our automotive grade L3/L4 autonomous driving software/ hardware, developed in collaboration with major automotive manufacturers, fully integrated with mass-produced heavy-duty freight trucks. With our advanced technology and seasoned operation team, we envision to develop the most trustworthy autonomous freight service network.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210312005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
